• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Weekly Overseas Health IT Links – 15th October, 2022.
This article uses the one that divides providers into groups depending on the life cycle stage the clinic is at the given moment. According to this classification, medical providers fall into three groups:BeginnersGrowing clinicsWell-established providersHealth care providers are business entities, so their life cycle, like that of any business, consists of the early stage or launch, growth and maturity. At each stage, providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.Medical software for beginnersThe launch phase can be tough. At this stage, the profits ...
Source: Australian Health Information Technology - October 15, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs

FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31  January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Media News - January 31, 2022 Category: Pharmaceuticals Source Type: news

The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Two papers in The Lancet highlight one-year results from Roche ’s phase III trials evaluatingfaricimab inneovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME)Across four studies, about half of eligiblefaricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longerReductions in central subfield thickness (CST) and resolution ofintraretinal fluid consistentlyfavouredfaricimab overaflibercept in DME, and meaningful and comparable CST reductions were seen innAMD in the first yearBasel, 24 January 2022 - Roche (SIX...
Source: Roche Media News - January 24, 2022 Category: Pharmaceuticals Source Type: news

FDA accepts application for Roche ’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)
Basel, 29 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA), under Priority Review, for faricimab for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The FDA has also accepted the company’s submission for diabetic retinopathy.Faricimab will be the first and only bispecific antibody designed for the eye, if approved. It targets two distinct pathways – via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) ...
Source: Roche Media News - July 29, 2021 Category: Pharmaceuticals Source Type: news

Fight Aging! Newsletter, August 24th 2020
We report that electrical stimulation (ES) stimulation of post-stroke aged rats led to an improved functional recovery of spatial long-term memory (T-maze), but not on the rotating pole or the inclined plane, both tests requiring complex sensorimotor skills. Surprisingly, ES had a detrimental effect on the asymmetric sensorimotor deficit. Histologically, there was a robust increase in the number of doublecortin-positive cells in the dentate gyrus and SVZ of the infarcted hemisphere and the presence of a considerable number of neurons expressing tubulin beta III in the infarcted area. Among the genes that were unique...
Source: Fight Aging! - August 23, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, July 2nd 2018
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - July 1, 2018 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs